Brief: Hillevax Announces Initiation Of Phase 2B Clinical Trial Of Hil-214 Vaccine Candidate For Prevention Of Acute Gastroenteritis In Infants
02/05/2022 13:18
May 2 (Reuters) - Hillevax Inc HLVX.O :
* HILLEVAX ANNOUNCES INITIATION OF PHASE 2B CLINICAL TRIAL
OF
HIL-214 VACCINE CANDIDATE FOR THE PREVENTION OF
NOROVIRUS-RELATED ACUTE GASTROENTERITIS IN INFANTS
Source text for Eikon: ID:nGNX57jPn5
Further company coverage: HLVX.O
((reuters.briefs@thomsonreuters.com;))
Recent news on HilleVax
See all newsBrief: XOMA Royalty Announces Closing Of Tender Offer For HilleVax
Brief: Hillevax Enters Into A Definitive Agreement To Be Acquired By Xoma Royalty For $1.95 In Cash Per Share Plus A Contingent Value Right
U.S. STOCKS ON THE MOVE-US energy sector, Oshkosh, Meta
U.S. STOCKS ON THE MOVE-Zumiez, BTC Digital, WesBanco
U.S. STOCKS ON THE MOVE-Petco Health, Smith & Wesson, Victoria's Secret